JP2013517487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517487A5
JP2013517487A5 JP2012549291A JP2012549291A JP2013517487A5 JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5 JP 2012549291 A JP2012549291 A JP 2012549291A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5
Authority
JP
Japan
Prior art keywords
tumor
cancer
antigen
cells
associated carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012549291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517487A (ja
Filing date
Publication date
Priority claimed from EP10000527A external-priority patent/EP2347769A1/en
Application filed filed Critical
Publication of JP2013517487A publication Critical patent/JP2013517487A/ja
Publication of JP2013517487A5 publication Critical patent/JP2013517487A5/ja
Ceased legal-status Critical Current

Links

JP2012549291A 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用 Ceased JP2013517487A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
EP10000527.1 2010-01-20
US61/296,738 2010-01-20
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015253064A Division JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Publications (2)

Publication Number Publication Date
JP2013517487A JP2013517487A (ja) 2013-05-16
JP2013517487A5 true JP2013517487A5 (enExample) 2014-02-06

Family

ID=42173400

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549291A Ceased JP2013517487A (ja) 2010-01-20 2011-01-20 がん幹細胞マーカーおよびその使用
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015253064A Withdrawn JP2016047848A (ja) 2010-01-20 2015-12-25 がん幹細胞マーカーおよびその使用

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Gpバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9341619B2 (en) 2013-03-14 2016-05-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hyposialylation disorders
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカAcademia Sinica 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
RU2699717C2 (ru) * 2014-04-18 2019-09-09 Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк Гуманизированные антитела к антигену Томсена-Фриденрайха
CN103969437B (zh) * 2014-04-22 2017-03-22 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Bacteroides由来のフコシダーゼおよびそれを使用する方法
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類iNKT細胞
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2016209056B2 (en) * 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカAcademia Sinica 新規なグリカンコンジュゲートおよびその使用方法
WO2016137963A1 (en) 2015-02-25 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sialylation-increasing therapies for diseases associated with oxidative stress
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類MUC1抗體Fab片段
TWI822055B (zh) * 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018178047A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Cd73抑制劑及a2a/a2b腺苷受體抑制劑組合療法
CN111363008B (zh) * 2020-03-18 2021-11-16 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用
AU2021298824A1 (en) * 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含a2a/a2b抑制劑、pd-1/pd-l1抑制劑及抗cd73抗體之組合療法
JP2024504406A (ja) * 2021-01-25 2024-01-31 ユニオジェン・オサケユフティオ 膀胱がんのバイオマーカーとしてのFUCα(1-2)Gal糖鎖構造の使用
US20240382590A1 (en) * 2021-07-16 2024-11-21 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN115960169A (zh) * 2021-10-09 2023-04-14 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN115197915B (zh) * 2022-08-01 2025-08-26 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
JP4904266B2 (ja) * 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−tf−抗原抗体の治療的使用
WO2007079448A2 (en) * 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
WO2007140011A2 (en) * 2006-05-26 2007-12-06 The Government Of The United States Of America Erythroid progenitor cells and methods for producing parvovirus b19 therein

Similar Documents

Publication Publication Date Title
JP2013517487A5 (enExample)
JP7274469B2 (ja) Cd39/cd73軸によるt細胞活性の回復
JP6491701B2 (ja) 新規モジュレーターと使用の方法
CN109970856B (zh) 抗lag-3抗体及其用途
Münz et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
JP2022537053A (ja) 抗tigit抗体
JP2013544493A5 (enExample)
JP7450585B2 (ja) CD66cに特異的に結合する抗体およびその用途
JP2017149720A5 (enExample)
JP2022507294A (ja) Cdcp1-標的化療法
WO2015161247A1 (en) Humanized anti-c16orf54 antibodies and methods of use thereof
WO2014068300A1 (en) Anti-s100a4 antibody molecules and their uses
CN114040774A (zh) 结合肿瘤组织用于诊断和治疗的抗体
JP2020125352A (ja) 抗−cd43抗体およびその癌治療用途
CN110944665A (zh) 用于预防或治疗肺癌的amhrii结合化合物
CN117304325A (zh) B7h3抗体及其用途
JP7165855B2 (ja) 骨髄由来抑制細胞関連疾患の予防および治療用途
BR112020023380A2 (pt) anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica
CN114907478A (zh) 结合lag-3的抗体及其用途
WO2024077774A1 (zh) 一种多功能重组抗体及其制备方法和应用
HK40113728A (zh) Claudin 18.2拮抗剂和pd-1/pd-l1轴抑制剂的组合疗法
CN118891287A (zh) 抗cd73的抗体及其应用
HK40009518A (en) Anti-lag-3 antibody and the use thereof
HK40009518B (en) Anti-lag-3 antibody and the use thereof
BR112019009771B1 (pt) Ligação de anticorpos especificamente à cd66c e utilização dos mesmos